Submit Manuscript  

Article Details

New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer

[ Vol. 17 , Issue. 3 ]


Rita Assi, Sally Temraz, Ali Shamseddine and Deborah Mukherji   Pages 290 - 302 ( 13 )


The androgen receptor (AR) signalling pathway remains a key driver of prostate cancer progression despite castrate levels of testosterone in advanced disease. The androgen biosynthesis inhibitor abiraterone and the anti-androgen enzalutamide have been shown to prolong survival in randomized clinical trials both pre-and post-docetaxel chemotherapy and are now in routine clinical use. With the use of these drugs and other novel survival-prolonging therapeutics, patients with advanced prostate cancer are now living longer with better quality of life. This article will review pre-clinical and clinical data for AR-targeting therapeutics for advanced prostate cancer with a focus on mechanisms of resistance and future directions for research.


Prostate cancer, androgen receptor, abiraterone, enzalutamide.


Department of Internal Medicine, Division of Hematology Oncology American University of Beirut Medical Center Beirut, Lebanon

Graphical Abstract:

Read Full-Text article